Bullous cutaneous reactions
Allopurinol (xanthine oxidase inhibitor) is indicated for the treatment of symptomatic hyperuricemia, the treatment of gout and the treatment and prevention of uric and calcium lithiasis. It is one of the leading drugs for severe toxic dermal reactions, such as Lyell Syndrome (NET), Stevens-Johnson...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Mohamed Jira [verfasserIn] Taoufik Amezyane [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch ; Französisch |
| Erschienen: |
2018 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: The Pan African Medical Journal ; 31(2018), 188 volume:31 ; year:2018 ; number:188 |
|---|
| Links: |
Link aufrufen |
|---|
| DOI / URN: |
10.11604/pamj.2018.31.188.16608 |
|---|
| Katalog-ID: |
DOAJ071711953 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ071711953 | ||
| 003 | DE-627 | ||
| 005 | 20230309103037.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230228s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.11604/pamj.2018.31.188.16608 |2 doi | |
| 035 | |a (DE-627)DOAJ071711953 | ||
| 035 | |a (DE-599)DOAJe0ad3515950342ecbf0cfec93960d307 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng |a fre | ||
| 100 | 0 | |a Mohamed Jira |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Bullous cutaneous reactions |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Allopurinol (xanthine oxidase inhibitor) is indicated for the treatment of symptomatic hyperuricemia, the treatment of gout and the treatment and prevention of uric and calcium lithiasis. It is one of the leading drugs for severe toxic dermal reactions, such as Lyell Syndrome (NET), Stevens-Johnson Syndrome (SJS) and Dress Syndrome (Drug reaction with eosinophilia and systemic symptoms). We report the case of a 45-year-old woman who was hospitalized for bullous skin rashes, without pathological history, the patient had generalized erythematous and bullous rash (A, B and C) one week after taking allopurinol, prescribed by his rheumatologist for a gout. The diagnosis of bullous Cutaneous reaction due to allopurinol was retained, allopurinol was discontinued and the course was favorable with the disappearance of cutaneous lesions. | ||
| 650 | 4 | |a allopurinol hypersensitivity | |
| 650 | 4 | |a bullous cataneous reactions | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 700 | 0 | |a Taoufik Amezyane |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t The Pan African Medical Journal |g 31(2018), 188 |
| 773 | 1 | 8 | |g volume:31 |g year:2018 |g number:188 |
| 856 | 4 | 0 | |u https://doi.org/10.11604/pamj.2018.31.188.16608 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/e0ad3515950342ecbf0cfec93960d307 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.panafrican-med-journal.com/content/article/31/188/pdf/188.pdf |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1937-8688 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1937-8688 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 31 |j 2018 |e 188 | ||
| author_variant |
m j mj t a ta |
|---|---|
| matchkey_str |
mohamedjirataoufikamezyane:2018----:uluctnose |
| hierarchy_sort_str |
2018 |
| publishDate |
2018 |
| allfields |
10.11604/pamj.2018.31.188.16608 doi (DE-627)DOAJ071711953 (DE-599)DOAJe0ad3515950342ecbf0cfec93960d307 DE-627 ger DE-627 rakwb eng fre Mohamed Jira verfasserin aut Bullous cutaneous reactions 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Allopurinol (xanthine oxidase inhibitor) is indicated for the treatment of symptomatic hyperuricemia, the treatment of gout and the treatment and prevention of uric and calcium lithiasis. It is one of the leading drugs for severe toxic dermal reactions, such as Lyell Syndrome (NET), Stevens-Johnson Syndrome (SJS) and Dress Syndrome (Drug reaction with eosinophilia and systemic symptoms). We report the case of a 45-year-old woman who was hospitalized for bullous skin rashes, without pathological history, the patient had generalized erythematous and bullous rash (A, B and C) one week after taking allopurinol, prescribed by his rheumatologist for a gout. The diagnosis of bullous Cutaneous reaction due to allopurinol was retained, allopurinol was discontinued and the course was favorable with the disappearance of cutaneous lesions. allopurinol hypersensitivity bullous cataneous reactions Medicine R Taoufik Amezyane verfasserin aut In The Pan African Medical Journal 31(2018), 188 volume:31 year:2018 number:188 https://doi.org/10.11604/pamj.2018.31.188.16608 kostenfrei https://doaj.org/article/e0ad3515950342ecbf0cfec93960d307 kostenfrei https://www.panafrican-med-journal.com/content/article/31/188/pdf/188.pdf kostenfrei https://doaj.org/toc/1937-8688 Journal toc kostenfrei https://doaj.org/toc/1937-8688 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 31 2018 188 |
| spelling |
10.11604/pamj.2018.31.188.16608 doi (DE-627)DOAJ071711953 (DE-599)DOAJe0ad3515950342ecbf0cfec93960d307 DE-627 ger DE-627 rakwb eng fre Mohamed Jira verfasserin aut Bullous cutaneous reactions 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Allopurinol (xanthine oxidase inhibitor) is indicated for the treatment of symptomatic hyperuricemia, the treatment of gout and the treatment and prevention of uric and calcium lithiasis. It is one of the leading drugs for severe toxic dermal reactions, such as Lyell Syndrome (NET), Stevens-Johnson Syndrome (SJS) and Dress Syndrome (Drug reaction with eosinophilia and systemic symptoms). We report the case of a 45-year-old woman who was hospitalized for bullous skin rashes, without pathological history, the patient had generalized erythematous and bullous rash (A, B and C) one week after taking allopurinol, prescribed by his rheumatologist for a gout. The diagnosis of bullous Cutaneous reaction due to allopurinol was retained, allopurinol was discontinued and the course was favorable with the disappearance of cutaneous lesions. allopurinol hypersensitivity bullous cataneous reactions Medicine R Taoufik Amezyane verfasserin aut In The Pan African Medical Journal 31(2018), 188 volume:31 year:2018 number:188 https://doi.org/10.11604/pamj.2018.31.188.16608 kostenfrei https://doaj.org/article/e0ad3515950342ecbf0cfec93960d307 kostenfrei https://www.panafrican-med-journal.com/content/article/31/188/pdf/188.pdf kostenfrei https://doaj.org/toc/1937-8688 Journal toc kostenfrei https://doaj.org/toc/1937-8688 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 31 2018 188 |
| allfields_unstemmed |
10.11604/pamj.2018.31.188.16608 doi (DE-627)DOAJ071711953 (DE-599)DOAJe0ad3515950342ecbf0cfec93960d307 DE-627 ger DE-627 rakwb eng fre Mohamed Jira verfasserin aut Bullous cutaneous reactions 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Allopurinol (xanthine oxidase inhibitor) is indicated for the treatment of symptomatic hyperuricemia, the treatment of gout and the treatment and prevention of uric and calcium lithiasis. It is one of the leading drugs for severe toxic dermal reactions, such as Lyell Syndrome (NET), Stevens-Johnson Syndrome (SJS) and Dress Syndrome (Drug reaction with eosinophilia and systemic symptoms). We report the case of a 45-year-old woman who was hospitalized for bullous skin rashes, without pathological history, the patient had generalized erythematous and bullous rash (A, B and C) one week after taking allopurinol, prescribed by his rheumatologist for a gout. The diagnosis of bullous Cutaneous reaction due to allopurinol was retained, allopurinol was discontinued and the course was favorable with the disappearance of cutaneous lesions. allopurinol hypersensitivity bullous cataneous reactions Medicine R Taoufik Amezyane verfasserin aut In The Pan African Medical Journal 31(2018), 188 volume:31 year:2018 number:188 https://doi.org/10.11604/pamj.2018.31.188.16608 kostenfrei https://doaj.org/article/e0ad3515950342ecbf0cfec93960d307 kostenfrei https://www.panafrican-med-journal.com/content/article/31/188/pdf/188.pdf kostenfrei https://doaj.org/toc/1937-8688 Journal toc kostenfrei https://doaj.org/toc/1937-8688 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 31 2018 188 |
| allfieldsGer |
10.11604/pamj.2018.31.188.16608 doi (DE-627)DOAJ071711953 (DE-599)DOAJe0ad3515950342ecbf0cfec93960d307 DE-627 ger DE-627 rakwb eng fre Mohamed Jira verfasserin aut Bullous cutaneous reactions 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Allopurinol (xanthine oxidase inhibitor) is indicated for the treatment of symptomatic hyperuricemia, the treatment of gout and the treatment and prevention of uric and calcium lithiasis. It is one of the leading drugs for severe toxic dermal reactions, such as Lyell Syndrome (NET), Stevens-Johnson Syndrome (SJS) and Dress Syndrome (Drug reaction with eosinophilia and systemic symptoms). We report the case of a 45-year-old woman who was hospitalized for bullous skin rashes, without pathological history, the patient had generalized erythematous and bullous rash (A, B and C) one week after taking allopurinol, prescribed by his rheumatologist for a gout. The diagnosis of bullous Cutaneous reaction due to allopurinol was retained, allopurinol was discontinued and the course was favorable with the disappearance of cutaneous lesions. allopurinol hypersensitivity bullous cataneous reactions Medicine R Taoufik Amezyane verfasserin aut In The Pan African Medical Journal 31(2018), 188 volume:31 year:2018 number:188 https://doi.org/10.11604/pamj.2018.31.188.16608 kostenfrei https://doaj.org/article/e0ad3515950342ecbf0cfec93960d307 kostenfrei https://www.panafrican-med-journal.com/content/article/31/188/pdf/188.pdf kostenfrei https://doaj.org/toc/1937-8688 Journal toc kostenfrei https://doaj.org/toc/1937-8688 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 31 2018 188 |
| allfieldsSound |
10.11604/pamj.2018.31.188.16608 doi (DE-627)DOAJ071711953 (DE-599)DOAJe0ad3515950342ecbf0cfec93960d307 DE-627 ger DE-627 rakwb eng fre Mohamed Jira verfasserin aut Bullous cutaneous reactions 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Allopurinol (xanthine oxidase inhibitor) is indicated for the treatment of symptomatic hyperuricemia, the treatment of gout and the treatment and prevention of uric and calcium lithiasis. It is one of the leading drugs for severe toxic dermal reactions, such as Lyell Syndrome (NET), Stevens-Johnson Syndrome (SJS) and Dress Syndrome (Drug reaction with eosinophilia and systemic symptoms). We report the case of a 45-year-old woman who was hospitalized for bullous skin rashes, without pathological history, the patient had generalized erythematous and bullous rash (A, B and C) one week after taking allopurinol, prescribed by his rheumatologist for a gout. The diagnosis of bullous Cutaneous reaction due to allopurinol was retained, allopurinol was discontinued and the course was favorable with the disappearance of cutaneous lesions. allopurinol hypersensitivity bullous cataneous reactions Medicine R Taoufik Amezyane verfasserin aut In The Pan African Medical Journal 31(2018), 188 volume:31 year:2018 number:188 https://doi.org/10.11604/pamj.2018.31.188.16608 kostenfrei https://doaj.org/article/e0ad3515950342ecbf0cfec93960d307 kostenfrei https://www.panafrican-med-journal.com/content/article/31/188/pdf/188.pdf kostenfrei https://doaj.org/toc/1937-8688 Journal toc kostenfrei https://doaj.org/toc/1937-8688 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 31 2018 188 |
| language |
English French |
| source |
In The Pan African Medical Journal 31(2018), 188 volume:31 year:2018 number:188 |
| sourceStr |
In The Pan African Medical Journal 31(2018), 188 volume:31 year:2018 number:188 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
allopurinol hypersensitivity bullous cataneous reactions Medicine R |
| isfreeaccess_bool |
true |
| container_title |
The Pan African Medical Journal |
| authorswithroles_txt_mv |
Mohamed Jira @@aut@@ Taoufik Amezyane @@aut@@ |
| publishDateDaySort_date |
2018-01-01T00:00:00Z |
| id |
DOAJ071711953 |
| language_de |
englisch franzoesisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ071711953</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309103037.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.11604/pamj.2018.31.188.16608</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ071711953</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJe0ad3515950342ecbf0cfec93960d307</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield><subfield code="a">fre</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Mohamed Jira</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Bullous cutaneous reactions</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Allopurinol (xanthine oxidase inhibitor) is indicated for the treatment of symptomatic hyperuricemia, the treatment of gout and the treatment and prevention of uric and calcium lithiasis. It is one of the leading drugs for severe toxic dermal reactions, such as Lyell Syndrome (NET), Stevens-Johnson Syndrome (SJS) and Dress Syndrome (Drug reaction with eosinophilia and systemic symptoms). We report the case of a 45-year-old woman who was hospitalized for bullous skin rashes, without pathological history, the patient had generalized erythematous and bullous rash (A, B and C) one week after taking allopurinol, prescribed by his rheumatologist for a gout. The diagnosis of bullous Cutaneous reaction due to allopurinol was retained, allopurinol was discontinued and the course was favorable with the disappearance of cutaneous lesions.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">allopurinol hypersensitivity</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">bullous cataneous reactions</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Taoufik Amezyane</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">The Pan African Medical Journal</subfield><subfield code="g">31(2018), 188</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:31</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:188</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.11604/pamj.2018.31.188.16608</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/e0ad3515950342ecbf0cfec93960d307</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.panafrican-med-journal.com/content/article/31/188/pdf/188.pdf</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1937-8688</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1937-8688</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">31</subfield><subfield code="j">2018</subfield><subfield code="e">188</subfield></datafield></record></collection>
|
| author |
Mohamed Jira |
| spellingShingle |
Mohamed Jira misc allopurinol hypersensitivity misc bullous cataneous reactions misc Medicine misc R Bullous cutaneous reactions |
| authorStr |
Mohamed Jira |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut |
| collection |
DOAJ |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
Bullous cutaneous reactions allopurinol hypersensitivity bullous cataneous reactions |
| topic |
misc allopurinol hypersensitivity misc bullous cataneous reactions misc Medicine misc R |
| topic_unstemmed |
misc allopurinol hypersensitivity misc bullous cataneous reactions misc Medicine misc R |
| topic_browse |
misc allopurinol hypersensitivity misc bullous cataneous reactions misc Medicine misc R |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
The Pan African Medical Journal |
| hierarchy_top_title |
The Pan African Medical Journal |
| isfreeaccess_txt |
true |
| title |
Bullous cutaneous reactions |
| ctrlnum |
(DE-627)DOAJ071711953 (DE-599)DOAJe0ad3515950342ecbf0cfec93960d307 |
| title_full |
Bullous cutaneous reactions |
| author_sort |
Mohamed Jira |
| journal |
The Pan African Medical Journal |
| journalStr |
The Pan African Medical Journal |
| lang_code |
eng fre |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2018 |
| contenttype_str_mv |
txt |
| author_browse |
Mohamed Jira Taoufik Amezyane |
| container_volume |
31 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Mohamed Jira |
| doi_str_mv |
10.11604/pamj.2018.31.188.16608 |
| author2-role |
verfasserin |
| title_sort |
bullous cutaneous reactions |
| title_auth |
Bullous cutaneous reactions |
| abstract |
Allopurinol (xanthine oxidase inhibitor) is indicated for the treatment of symptomatic hyperuricemia, the treatment of gout and the treatment and prevention of uric and calcium lithiasis. It is one of the leading drugs for severe toxic dermal reactions, such as Lyell Syndrome (NET), Stevens-Johnson Syndrome (SJS) and Dress Syndrome (Drug reaction with eosinophilia and systemic symptoms). We report the case of a 45-year-old woman who was hospitalized for bullous skin rashes, without pathological history, the patient had generalized erythematous and bullous rash (A, B and C) one week after taking allopurinol, prescribed by his rheumatologist for a gout. The diagnosis of bullous Cutaneous reaction due to allopurinol was retained, allopurinol was discontinued and the course was favorable with the disappearance of cutaneous lesions. |
| abstractGer |
Allopurinol (xanthine oxidase inhibitor) is indicated for the treatment of symptomatic hyperuricemia, the treatment of gout and the treatment and prevention of uric and calcium lithiasis. It is one of the leading drugs for severe toxic dermal reactions, such as Lyell Syndrome (NET), Stevens-Johnson Syndrome (SJS) and Dress Syndrome (Drug reaction with eosinophilia and systemic symptoms). We report the case of a 45-year-old woman who was hospitalized for bullous skin rashes, without pathological history, the patient had generalized erythematous and bullous rash (A, B and C) one week after taking allopurinol, prescribed by his rheumatologist for a gout. The diagnosis of bullous Cutaneous reaction due to allopurinol was retained, allopurinol was discontinued and the course was favorable with the disappearance of cutaneous lesions. |
| abstract_unstemmed |
Allopurinol (xanthine oxidase inhibitor) is indicated for the treatment of symptomatic hyperuricemia, the treatment of gout and the treatment and prevention of uric and calcium lithiasis. It is one of the leading drugs for severe toxic dermal reactions, such as Lyell Syndrome (NET), Stevens-Johnson Syndrome (SJS) and Dress Syndrome (Drug reaction with eosinophilia and systemic symptoms). We report the case of a 45-year-old woman who was hospitalized for bullous skin rashes, without pathological history, the patient had generalized erythematous and bullous rash (A, B and C) one week after taking allopurinol, prescribed by his rheumatologist for a gout. The diagnosis of bullous Cutaneous reaction due to allopurinol was retained, allopurinol was discontinued and the course was favorable with the disappearance of cutaneous lesions. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ |
| container_issue |
188 |
| title_short |
Bullous cutaneous reactions |
| url |
https://doi.org/10.11604/pamj.2018.31.188.16608 https://doaj.org/article/e0ad3515950342ecbf0cfec93960d307 https://www.panafrican-med-journal.com/content/article/31/188/pdf/188.pdf https://doaj.org/toc/1937-8688 |
| remote_bool |
true |
| author2 |
Taoufik Amezyane |
| author2Str |
Taoufik Amezyane |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.11604/pamj.2018.31.188.16608 |
| up_date |
2024-07-03T21:47:04.736Z |
| _version_ |
1803596044424970240 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ071711953</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309103037.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.11604/pamj.2018.31.188.16608</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ071711953</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJe0ad3515950342ecbf0cfec93960d307</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield><subfield code="a">fre</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Mohamed Jira</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Bullous cutaneous reactions</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Allopurinol (xanthine oxidase inhibitor) is indicated for the treatment of symptomatic hyperuricemia, the treatment of gout and the treatment and prevention of uric and calcium lithiasis. It is one of the leading drugs for severe toxic dermal reactions, such as Lyell Syndrome (NET), Stevens-Johnson Syndrome (SJS) and Dress Syndrome (Drug reaction with eosinophilia and systemic symptoms). We report the case of a 45-year-old woman who was hospitalized for bullous skin rashes, without pathological history, the patient had generalized erythematous and bullous rash (A, B and C) one week after taking allopurinol, prescribed by his rheumatologist for a gout. The diagnosis of bullous Cutaneous reaction due to allopurinol was retained, allopurinol was discontinued and the course was favorable with the disappearance of cutaneous lesions.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">allopurinol hypersensitivity</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">bullous cataneous reactions</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Taoufik Amezyane</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">The Pan African Medical Journal</subfield><subfield code="g">31(2018), 188</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:31</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:188</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.11604/pamj.2018.31.188.16608</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/e0ad3515950342ecbf0cfec93960d307</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.panafrican-med-journal.com/content/article/31/188/pdf/188.pdf</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1937-8688</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1937-8688</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">31</subfield><subfield code="j">2018</subfield><subfield code="e">188</subfield></datafield></record></collection>
|
| score |
7.4009523 |